Craft

Sopharma

Revenue

ЛВ2.6 B

FY, 2025

Sopharma Summary

Company Summary

Overview
Sopharma researches and develops, produces, and trades in medicinal substances, finished drug forms, veterinary vaccines, infusion solutions, and medical disposable products for human and veterinary medicine, and food supplements. It offers products in various therapeutic areas. The Company also produces and trades in dressing and sanitary-hygienic materials, as well as products for dentistry and food supplements, provides secondary packaging services, trading, transportation, and packaging services for radioactive materials and nuclear equipment for medicinal use, household electronics, and electrical equipment, and purchases, collects, grows, produces, and trades in herbs and medicinal plants. In addition, the Company engages in the retail trade of medical equipment, production of non-medicinal, and other products, and franchising, know-how, and rental of properties, as well as in trading, consulting, and other activities. Further, it offers market and public opinion research services, concentrates for hemodialysis, and injection molded products for the industry, agriculture, and households.
Type
Public
Status
Active
Founded
1933
HQ
Sofia, BG | view all locations
Website
http://www.sopharmagroup.com/
Cybersecurity rating
Sectors

Key People

  • Ognian Ivanov Donev

    Ognian Ivanov Donev, Chairman of the Board of Directors and Executive Director

    • Vessela Liubenova Stoeva

      Vessela Liubenova Stoeva, Deputy-Chairman of the Board of Directors

      LocationsView all

      5 locations detected

      • Sofia, Sofia City Province HQ

        Bulgaria

        ul. "Lachezar Stanchev" 5

      • Sofia, Sofia City Province

        Bulgaria

        ул. "Илиенско шосе" No 8

      • Almaty, Almaty Province

        Kazakhstan

        Mamyr-4 Microdistrict

      • Warszawa, mazowieckie

        Poland

        al. Jerozolimskie 13602

      • Kyiv

        Ukraine

        Heroiv Stalinhrada Ave, 53Б

      Sopharma Financials

      Summary Financials

      Revenue (FY, 2025)
      лв2.6B
      Gross profit (FY, 2025)
      лв585.9M
      Net income (FY, 2025)
      лв136.6M
      Cash (FY, 2025)
      лв71.7M
      EBIT (FY, 2025)
      лв189.7M

      Footer menu